Stockscreener 앱 받기
2.68
6.35%
0.16
시간 외 거래:
2.76
0.08
+2.99%
전일 마감가:
$2.52
열려 있는:
$2.53
하루 거래량:
968.80K
Relative Volume:
0.71
시가총액:
$23.72M
수익:
-
순이익/손실:
$-30.16M
주가수익비율:
-7.8824
EPS:
-0.34
순현금흐름:
$-39.49M
1주 성능:
-13.27%
1개월 성능:
-4.96%
6개월 성능:
-19.52%
1년 성능:
-24.29%
1일 변동 폭
$2.49
$2.8299
1주일 범위
$2.44
$3.19
52주 변동 폭
$2.11
$9.19
Dare Bioscience Inc Stock (DARE) Company Profile
명칭
Dare Bioscience Inc
전화
858-926-7655
주소
3655 NOBEL DRIVE, SAN DIEGO, CA
DARE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DARE
Dare Bioscience Inc
|
2.68 | 27.35M | 0 | -30.16M | -39.49M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Dare Bioscience Inc 주식(DARE)의 최신 뉴스
UPDATEDaré Bioscience to Host August 6 Webinar: The DARE - GlobeNewswire
Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ DifferenceThe Sildenafil Cream That Raises the Bar - GlobeNewswire
Daré Bioscience Reports Positive Contraception Trial Results as Smart Drug Delivery Platform Shows Broader Potential - Femtech Insider
Dare Bioscience stock holds Buy rating at H.C. Wainwright on positive trial data - Investing.com Canada
3 Penny Stocks to Watch Now, 7/15/25 - TipRanks
Daré Bioscience reports positive interim results for hormone-free contraceptive - Investing.com Australia
Small Healthcare Stocks Enjoy Big Wins On Deal News - Finimize
Dare Bioscience Surges to 200th in Market Rankings with $47.4 Million Turnover - AInvest
Douglas Tsao Recommends ‘Buy’ for Daré Bioscience: Ovaprene’s Promising Potential and Financial Prospects - TipRanks
Crude Oil Moves Lower; Daré Bioscience Shares Jump - inkl
Dare reports interim safety, efficacy results from Phase 3 trial of Ovaprene - TipRanks
Daré Bioscience stock soars after positive interim Phase 3 contraceptive results - Investing.com India
Daré Bioscience Soars 250% on Positive Ovaprene Trial Data - Wall Street Pit
Dare Bioscience’s Unforeseen Stock Skyward Leap - StocksToTrade
US Stocks Edge Lower; Fastenal Posts Upbeat Earnings - Benzinga
Dare Bioscience Reflects on Grant Milestone - timothysykes.com
Daré Bioscience reports positive interim results for hormone-free contraceptive By Investing.com - Investing.com South Africa
Why Is Daré Bioscience Stock (DARE) Up 240% Today? - TipRanks
Dare Bioscience Announces Positive Results From Hormone-Free Contraceptive Trial; Shares Surge - MarketScreener
Daré Bioscience Announces Positive Phase 3 Trial Results - TipRanks
Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive - The Manila Times
Daré Bioscience Announces Positive Interim Results from Phase 3 Trial of Hormone-Free Contraceptive Ovaprene® - Quiver Quantitative
Dare Bioscience Plunges 11.33% Amid Market Shifts - AInvest
Daré Bioscience receives $6 million installment for contraceptive device - Investing.com Australia
Daré Bioscience Receives $6 Million Non-Dilutive Grant - GlobeNewswire
Dare Bioscience Sees Stock Surge Amid Strategic Collaborations - StocksToTrade
Daré Bioscience receives $6 million installment for contraceptive device By Investing.com - Investing.com South Africa
Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders - GlobeNewswire
Daré's Smart Drug Delivery Platform Secures $6M Grant, Eyes Expansion into $B Obesity Market - Stock Titan
Dare Bioscience shareholders approve board nominees and stock plan amendment - Investing.com
Daré Bioscience Stockholder Meeting Approves Key Proposals - TipRanks
Daré Bioscience Gains Nasdaq Compliance Extension Approval - TipRanks
Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders | DARE Stock News - GuruFocus
Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders - GlobeNewswire
Daré Bioscience Stockholders Must Vote by July 8 for Crucial Annual Meeting - Stock Titan
Daré Bioscience Announces Corporate Presentation for Investors - TipRanks
Brokers Offer Predictions for Daré Bioscience Q1 Earnings - Defense World
Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
H.C. Wainwright maintains Buy rating on Dare Bioscience stock By Investing.com - Investing.com Canada
Daré Bioscience partners with Rosy Wellness for new women’s health cream By Investing.com - Investing.com South Africa
Daré Bioscience and Rosy Wellness Announce Strategic - GlobeNewswire
Daré Bioscience partners with Rosy Wellness for new women’s health cream - Investing.com
Dare Bioscience (DARE) Joins Forces with Rosy Wellness for Product Campaign | DARE Stock News - GuruFocus
Daré Bioscience and Rosy Wellness Announce Strategic Collaboration to Educate and Market Daré’s DARE to PLAY Sildenafil Cream - Yahoo Finance
Daré Bioscience, Rosy Wellness to Collaborate on DARE to PLAY Sildenafil Cream Marketing - AInvest
Dare Bioscience secures additional NIAID funding for HPV treatment - MSN
Q2 EPS Estimate for Daré Bioscience Increased by Analyst - Defense World
Daré outlines expanded dual path strategy targeting $4.5B hormone therapy market while accelerating commercialization in Q4 2025 - MSN
Daré Bioscience’s Earnings Call: Strategic Moves Amid Challenges - TipRanks
Daré Bioscience, Inc. (NASDAQ:DARE) Q1 2025 Earnings Call Transcript - Insider Monkey
Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates - MSN
Dare Bioscience Inc (DARE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
0.17%
자본화:
|
볼륨(24시간):